

Indication	Target	Candidate	Research	Hit	Lead	Pre-clinic	FIH Phase 0	Phase I	Phase II	Sponsor / Licensee
FAP Expressing Tumors	Fibroblast Activation Protein (FAP)	FAP-2286	¹⁷⁷ Lu							NOVARTIS
FAP Expressing Tumors	Fibroblast Activation Protein (FAP)	FO-004	¹⁷⁷ Lu							3B Pharmaceuticals
FAP Expressing Tumors	Fibroblast Activation Protein (FAP)	RXM-5201	⁶⁸ Ga							SCINTIX BIOLOGY-GUIDED RADIOTHERAPY reflexion
FAP Expressing Tumors	Fibroblast Activation Protein (FAP)	3BP-4961 SPECTROFAP	^{99m} Tc							3B Pharmaceuticals
NTR Expressing Tumors	Neurotensin Receptor (NTR)	FPI-2059 (IPN-01087) (3BP-227)	²²⁵ Ac				¹⁷⁷ Lu			Fusion Pharmaceuticals Inc.
Neuroendocrine Tumors	Gastric Inhibitory Polypeptide Receptor (GIP-R)	3BP-3775	¹⁷⁷ Lu							3B Pharmaceuticals
CAIX Expressing Tumors	Carbonic Anhydrase IX (CAIX)	DPI-4452	¹⁷⁷ Lu							Debiopharm
Prostate Cancer	Prostate-Specific Membrane Antigen PSMA	3BP	²²⁵ Ac, ¹⁷⁷ Lu							3B Pharmaceuticals
Small Cell Lung Cancer	Delta-like Ligand-3 DLL3	3BP								3B Pharmaceuticals
Solid Tumors	Undisclosed	3BP								3B Pharmaceuticals
Solid Tumors	P-Cadherin	3BP	¹⁷⁷ Lu							3B Pharmaceuticals
Solid Tumors	Urokinase-Type Plasminogen Activator Receptor (uPAR)	3BP	¹⁷⁷ Lu							3B Pharmaceuticals
Solid Tumors	Undisclosed	3BP								3B Pharmaceuticals
Solid Tumors	Undisclosed	3BP								3B Pharmaceuticals
Solid Tumors	Undisclosed	3BP								3B Pharmaceuticals

 THERAPEUTIC RADIOPHARMACEUTICAL

 SPECT OR PET IMAGING AGENT